Recent Security Class Actions

ESSA Pharma Inc. Common Stock (NASDAQ: EPIX)

21 Days left to seek lead plaintiff status.

Company Name:ESSA Pharma Inc. Common Stock
Stock Symbol:NASDAQ: EPIX
Class Period Start:12/12/2023
Class Period End (inclusive):10/31/2024
Filing Deadline:03/25/2025

The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and prospects. Specifically, the Complaint alleges Defendants made false and/or misleading statements and/or failed to disclose that: (i) masofaniten in combination with enzalutamide had no clear efficacy benefit over enzalutamide alone; (ii) accordingly, masofaniten in combination with enzalutamide was less effective in treating prostate cancer than Defendants had led investors to believe; (iii) the M-E Combination Study was unlikely to meet its prespecified Phase 2 primary endpoint; (iv) accordingly, Defendants had overstated masofaniten's clinical, regulatory, and commercial prospects; and (v) as a result, Defendants' public statements were materially false and misleading at all relevant times.

ESSA Pharma Inc. Common Stock (NASDAQ: EPIX) Claim Form

Name(Required)
Address
This field is for validation purposes and should be left unchanged.